ErbB4 and its isoforms: Patentable drug targets?

Recent Patents on DNA and Gene Sequences

Volumn 2, Issue 1, 2008, Pages 27-33

  Paatero, Ilkka ^a   Elenius, Klaus ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cancer; Heart disease; HER; Neuregulins; Receptor tyrosine kinases; Schizoplhrenia; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR 4 AGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR 4 ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR 4 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYBRID PROTEIN; ISOPROTEIN; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR AGONIST; NEU DIFFERENTIATION FACTOR ANTAGONIST; NEUROLEPTIC AGENT; PACLITAXEL; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; BINDING AFFINITY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGENITAL HEART DISEASE; DIAGNOSTIC TEST; DISEASE MARKER; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HUMAN; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MYOCARDITIS; NONHUMAN; PATENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN VARIANT; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; HEART DISEASES; HUMANS; NEOPLASMS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SCHIZOPHRENIA;

EID: 42249083438     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221508783406602     Document Type: Review

References (84)

1. Yarden, Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
2. Normanno, N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
3. Bublil EM, Yarden Y. The EGF receptor family: Spearheading merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19: 124-134.
4. Plowman, G.D., Culouscou, J., Shoyab, M.: EP0599274 (1994).
5. Junttila TT, Sundvall M, Maatta JA, Elenius K. Erbb4 and its isoforms: Selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000; 10: 304-310.
6. Maatta JA, Sundvall M, Junttila TT, et al. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 2006; 17: 67-79.
7. Elenius Y, Corfas G, Paul S, et al. A novel juxtamembrane domain isoform of HER4/ErbB4. isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 1997; 272: 26761-26768.
8. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 2000; 275: 10379-87.
9. Ni CY, Murphy MP, Golde TE, Carpenter G. Gamma -secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294: 2179-2181
10. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 2003; 15: 143-148.
11. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999; 18: 2607-2615.
12. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341
13. Aqeilan RI, Donati V, Gaudio E, et al. Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007; 67: 9330-9336.
14. Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993; 366: 473-475.
15. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 1997; 16: 1268-1278.
16. Anklesaria P, Teixido J, Laiho M, Pierce JH, Greenberger JS, Massague J. Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. Proc Natl Acad Sci USA 1990; 87: 3289-3293.
17. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003; 284: 14-30.
18. Yamada K, Ichino N, Nishii K, et al. Characterization of the human NTAK gène structure and distribution of the isoforms for rat, NTAK mRNA. Gene 2000; 255: 15-24.
19. Carteron C, Ferrer-Montiel A, Cabedo H. Characterization of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival. J Cell Sci 2006; 119: 898-909.
20. Hayes NV, Blackburn E, Smart LV, et al. Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer. Clin Cancer Res 2007; 13: 3147-55.
21. Loukianov E, Loukianova T, Wiedlocha A, Olsnes S.Expression of mRNA for a short form of heparin-binding EGF-like growth factor. Gene 1997; 195: 81-86.
22. Dunbar AJ, Goddard C. Identification of an alternatively spliced mRNA transcript of human betacellulin lacking the C-loop of the EGF motif and the transmembrane domain. Growth Factors 2000; 18: 169-175.
23. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-80.
24. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002; 8: 3054-3064.
25. Junttila TT, Laato M, Vahlberg T, et al. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin. Cancer Res 2003; 9: 5346-5357.
26. Kountourakis P, Pavlakis K, Psyrri A, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006; 6: 46.
27. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004; 64: 2047-53.
28. Thybusch-Bernhardt A, Beckmann S, Juhl H. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HEk-4 correlates with a favourable tumor stage. Int J Surg Investig 2001; 2: 393-400.
29. Thomasson M, Hedman H, Junttila TT, Elenius K, Ljungberg B, Henriksson R. ErbB4 is downregulated in renal cell carcinoma - a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol 2004; 43: 453-459.
30. Suo Z, Emilsen E, Tveit KM, Nesland JM. Type 1 protein tyrosine kinases in benign and malignant breast lesions. Histopathology 1998; 33: 514-521.
31. Vogt U, Bielawski K, Schlotter CM, Bosse U, Falkiewicz B, Podhajska AJ. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 1998; 223: 375-380.
32. Junttila TT, Sundvall M, Lundin M, et al. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 2005; 65: 1384-1393.
33. Gullick WJ. c-erbB-4/HER4: friend or foe? J Pathol 2003; 200: 279-281.
34. Bieche I, Onody P, Tozlu S, et al. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106: 758-765.
35. Lodge AJ, Anderson JJ, Gullick WJ, Haugh B, Leonard RC, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J. Clin Pathol 2003; 56: 300-304.
36. Pawlowski V, Revillion F, Hebbar M, Homez L, and Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 4217-4225.
37. Suo Z, Risberg B, Kalsson MG, et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002; 196: 17-25.
38. Knowlden JM, Gee JM, Seery LT, et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998; 17: 1949-1957.
39. Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 1999; 147: 77-88.
40. Peles E, Bacus SS, Koski RA, et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992; 69: 205-216.
41. Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999; 59: 5315-5322.
42. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000; 275: 8641-8649.
43. Sundvall M, Peri L, Maatta JA, et al. Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene 2007; 26: 6905-6914.
44. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006; 118: 1426-1429.
45. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
46. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
47. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436: 792.
48. Nicodemus KK, Luna A, Vakkalanka R, et al. Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Mol Psychiatry 2006; 11: 1062-1065.
49. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 142-148.
50. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., et al. Neuregulin I and susceptibility to schizophrenia. Am J Hum Genet 2002; 71:877-892.
51. Norton N, Moskvina V, Morris DW, et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 96-101.
52. Li D, Collier DA, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006; 15: 1995-2002.
53. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006; 60: 132-140.
54. Okada M, Corfas G. Neuregulin1 downregulates postsynaptic GABAA receptors at the hippocampal inhibitory synapse. Hippocampus 2004; 14: 337-344.
55. Woo RS, Li XM, Tao Y, et al. Neuregulin-1 enhances depolarization-induced GABA release. Neuron 2007; 54: 599-610.
56. Li B, Woo RS, Mei L, Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007; 54: 583-597.
57. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12: 824-828.
58. Law A.J., Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 2007; 16: 129-141.
59. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-394.
60. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-390.
61. Iwamoto R, Yamazaki S, Asakura M, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA. 2003; 100: 3221-3226.
62. Garcia-Rivello H, Taranda J, Said M, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol 2005; 289: H1153-160.
63. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261-10269.
64. Iivanainen E, Paatero I, Heikkinen SM, et al. Intra- and extra-cellular signaling by endothelial neuregulin-1. Exp Cell Res 2007; 313: 2896-2909.
65. Amin DN, Hida K, Bielenberg DR, and Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (BGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors Cancer Res 2006; 66: 2173-2180.
66. Iivanainen E, Nelimarkka L, Elenius V, et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor FASEB J 2003; 17: 1609-1621.
67. Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models, of ischemic, dilated, and viral cardiomyopathy J Am Coll Cardiol 2006; 48: 1438-1447.
68. Van Zoelen, E. J. J., Van der Woning, S. P.: WO07065464 (2007).
69. Shewchuk, L.M., Hassell, A.M., and Brignola, P.S.: WO04066921 (2004).
70. Bouyain S, Longo PA, Li S, Ferguson KM, and Leahy DJ. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand Proc Natl Acad Sci USA 2005; 102: 15024-15029.
71. Loeb, J.A.: WO06017184 (2006).
72. Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 1998; 431: 102-106.
73. Zhou, M.: US7226907 (2007).
74. Zhang D, Sliwkowski,MX, Mark M, et al. Neuregulin-3 (NRG3): a novel neural tissue enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 1997; 94: 9562-9567.
75. Harari D, Tzahar E, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999; 18: 2681-2689.
76. Godowski, P.J;, Mark, M.R., Zhang D-X.: WO9002681 (1999).
77. Harari, D., Yarden, Y.: US20067094882 (2006).
78. Schleyer, S.C., Jefferson, A. B., Abraham, J.A., Kavanaugh, W.M.: US20077198999 (2007).
79. Zhou, M.: WO07062594 (2007).
80. Ballinger, M.D., Jones, J.T., Faribrother, W.J., Sliwkowski, M.X., Wells, J.A.: US20067063961 (2006).
81. Stefansson, H., Steinthorsdottir, V., Gulcher, J.R., Gurney, M.; Andresson, T.: WO03020911 (2003).
82. Gerritsen, M.E., Sliwkowski, M.X.: WO0218444 (2002).
83. Jacquemir, J., Bertucci, F., Birnbaum, D., Debono, S., Tagett, R.: WO05071419 (2005).
84. Baker, J.B., Shak, S., Gianni, L.: WO05100606 (2005).